MA52375B2 - Inhibiteurs de cdk8/19 - Google Patents

Inhibiteurs de cdk8/19

Info

Publication number
MA52375B2
MA52375B2 MA52375A MA52375A MA52375B2 MA 52375 B2 MA52375 B2 MA 52375B2 MA 52375 A MA52375 A MA 52375A MA 52375 A MA52375 A MA 52375A MA 52375 B2 MA52375 B2 MA 52375B2
Authority
MA
Morocco
Prior art keywords
cdk8
inhibitors
compounds
disorders
possess
Prior art date
Application number
MA52375A
Other languages
English (en)
Other versions
MA52375A1 (fr
Inventor
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Mariia Andreevna Kasatkina
Elena Aleksandrovna Maksimenko
Aleksei Leonidovich Mindich
Anna Jur'evna Chestnova
Andrei Ivanovich Alafinov
Aleksei Sergeevich Gavrilov
Anton Aleksandrovich Evdokimov
Liliana Vyacheslavovna Lenshmidt
Mariia Sergeevna Mishina
Sergei Aleksandrovich Silonov
Evgenii Jur'evich Smirnov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA52375A1 publication Critical patent/MA52375A1/fr
Publication of MA52375B2 publication Critical patent/MA52375B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux composés correspondant à la formule (i) qui possèdent des propriétés d'inhibiteur de cdk8/19, ainsi que des compositions pharmaceutiques contenant lesdits composés, et leur utilisation en qualité de préparations pharmaceutiques pour traiter des affections ou des troubles.
MA52375A 2018-08-03 2019-07-31 Inhibiteurs de cdk8/19 MA52375B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
PCT/RU2019/050123 WO2020027704A1 (fr) 2018-08-03 2019-07-31 Inhibiteurs de cdk8/19

Publications (2)

Publication Number Publication Date
MA52375A1 MA52375A1 (fr) 2021-12-31
MA52375B2 true MA52375B2 (fr) 2023-02-28

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52375A MA52375B2 (fr) 2018-08-03 2019-07-31 Inhibiteurs de cdk8/19

Country Status (19)

Country Link
US (1) US11840531B2 (fr)
EP (1) EP3831829A4 (fr)
JP (1) JP7365396B2 (fr)
KR (1) KR102926889B1 (fr)
CN (1) CN113166140B (fr)
AR (1) AR115898A1 (fr)
AU (1) AU2019313199B2 (fr)
BR (1) BR112021001939A2 (fr)
CA (1) CA3108298A1 (fr)
CL (1) CL2021000282A1 (fr)
CO (1) CO2021001174A2 (fr)
EA (1) EA202190452A1 (fr)
MA (1) MA52375B2 (fr)
MX (1) MX2021001335A (fr)
PE (1) PE20210416A1 (fr)
PH (1) PH12021550258A1 (fr)
RU (1) RU2761824C2 (fr)
TW (1) TWI839374B (fr)
WO (1) WO2020027704A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (fr) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Inhibiteurs de cdk

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20100298359A1 (en) 2007-12-06 2010-11-25 Xianhai Huang Gamma secretase modulators
EP2630122B1 (fr) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Dérivés d'arylamide en tant qu'agents bloquants de ttx-s
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
CA2950238A1 (fr) * 2014-07-17 2016-01-21 Merck Patent Gmbh Nouvelles naphtyridines et isoquinoleines et leur utilisation a titre d'inhibiteurs de cdk8/19
EP3383875B1 (fr) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research Pyridines 3-pyrimidinyl pyrrolo [2,3-b] utilisées comme agents anticancéreux et leur procédé de préparation
EP3464267B1 (fr) * 2016-05-23 2020-09-23 Boehringer Ingelheim International GmbH Nouveaux composés de phenylpyrazolylacetamide et dérivés en tant qu'inhibiteurs de cdk8/cdk19

Also Published As

Publication number Publication date
PH12021550258A1 (en) 2021-10-11
CN113166140A (zh) 2021-07-23
TW202012406A (zh) 2020-04-01
EP3831829A4 (fr) 2022-04-20
MA52375A1 (fr) 2021-12-31
EA202190452A1 (ru) 2021-04-13
BR112021001939A2 (pt) 2021-04-27
JP2021533143A (ja) 2021-12-02
CO2021001174A2 (es) 2021-02-26
PE20210416A1 (es) 2021-03-04
AU2019313199B2 (en) 2023-07-06
JP7365396B2 (ja) 2023-10-19
KR102926889B1 (ko) 2026-02-19
AU2019313199A1 (en) 2021-03-11
TWI839374B (zh) 2024-04-21
EP3831829A1 (fr) 2021-06-09
KR20210040416A (ko) 2021-04-13
CA3108298A1 (fr) 2020-02-06
MX2021001335A (es) 2021-04-12
US20210246138A1 (en) 2021-08-12
RU2018128415A3 (fr) 2021-03-30
CN113166140B (zh) 2024-06-14
AR115898A1 (es) 2021-03-10
RU2761824C2 (ru) 2021-12-13
WO2020027704A1 (fr) 2020-02-06
CL2021000282A1 (es) 2021-08-13
RU2018128415A (ru) 2020-02-04
US11840531B2 (en) 2023-12-12

Similar Documents

Publication Publication Date Title
MA57972B1 (fr) Inhibiteurs de parp1
MA51530B1 (fr) Composés cycliques fondus
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA54133A (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA34599B1 (fr) Compositions pharmaceutiques contenant un inhibiteur dgat1
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA52375A1 (fr) Inhibiteurs de cdk8/19
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
MA48238B1 (fr) Nouveaux composes heterocyclique comme inhibiteurs de cdk8/19